Gainey McKenna & Egleston, a seasoned civil litigation firm, has initiated a class action lawsuit against Lantheus Holdings, Inc. (NASDAQ: LNTH), a prominent player in the radiopharmaceutical industry. The lawsuit was filed in the U.S. District Court for the Southern District of New York, representing investors who acquired Lantheus stock between February 26, 2025, and August 5, 2025.

At the heart of the lawsuit are allegations that Lantheus provided misleading information to its shareholders regarding the market competition and pricing strategies for Pylarify, its leading prostate cancer imaging agent. The complaint details that despite positive public assertions by Lantheus executives, the company faced significant competitive pricing pressures which they failed to adequately assess or disclose. Notably, a price increase in early 2025 was implemented amidst signs of declining prices from the previous year, potentially setting the stage for competitors to capitalize on the situation.

These strategic missteps reportedly jeopardized the pricing stability, revenue generation, and growth prospects of Pylarify. The ramifications of these actions became apparent when Lantheus announced a significant 8.3% decline in Pylarify sales year-over-year in early August, leading to a drastic revision of their full-year financial projections. This disclosure resulted in Lantheus’s stock price plummeting nearly 30% in just one trading day, prompting significant investor concern and financial loss.

Investors affected by the stock’s downturn during the specified period have the opportunity to join the class action lawsuit. The court has set November 10, 2025, as the deadline for potential lead plaintiffs—investors willing to represent the class—to come forward.

For further details or to participate in the lawsuit, investors are encouraged to directly reach out to Thomas J. McKenna, Esq., or Gregory M. Egleston, Esq., via their provided email addresses, or by calling Gainey McKenna & Egleston at (212) 983-1300.

Lantheus Holdings, headquartered in Bedford, Massachusetts, has been at the forefront of radiodiagnostic and therapeutic innovations since its inception in 1956. The company has been instrumental in developing and bringing to market several FDA-approved products aimed at enhancing patient care through advanced medical imaging and targeted treatments.

The legal challenge comes at a time when Lantheus was positioning itself as a leader in both the diagnostics and therapeutic fields, making this lawsuit a critical event that could potentially influence its future operations and market position. Investors and market watchers are keenly observing the developments of this case, as its outcome could have far-reaching implications for corporate governance and investor relations in the biotech and pharmaceutical industries.